Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Arana-Luna, Luara L.; Alvarado-Ibarra, Martha; Silva-Michel, Luis G.; Morales-Maravilla, Adrián; González-Rubio, María del C.; Chávez-Aguilar, Lénica A.; Tena-Iturralde, María Fernanda; Mojica-Balceras, Liliana; Zapata-Canto, Nidia; Galindo-Delgado, Patricia; Miranda-Madrazo, María Raquel; Morales-Hernández, Alba E.; Silva-Vera, Karina; Grimaldo-Gómez, Flavio A.; Hernández-Caballero, Álvaro; Bates-Martin, Ramón A.; Álvarez-Vera, José L.; Tepepa-Flores, Fredy; Teomitzi-Sánchez, Óscar; Fermín-Caminero, Denisse J.; Peña-Celaya, José A. de la; Salazar-Ramírez, Óscar; Flores-Villegas, Luz V.; Guerra-Alarcón, Lidia V.; Leyto-Cruz, Faustino; Inclán-Alarcón, Sergio I.; Milán-Salvatierra, Andrea I.; Ventura-Enríquez, Yanet; Pérez-Lozano, Uendy; Báez-Islas, Pamela E.; Tapia-Enríquez, Ana L.; Palma-Moreno, Orlando G.; Aguilar-Luévano, Jocelyn; Espinosa-Partida, Arturo; Pérez-Jacobo, Luis F.; Rojas-Castillejos, Flavio; Ruiz-Contreras, Josué I.; Loera-Fragoso, Sergio J.; Medina-Coral, Jesús E.; Acosta-Maldonado, Brenda L.; Soriano-Mercedes, Emely J.; Saucedo-Montes, Erick E.; Valero-Saldana, Luis M.; González-Prieto, Susana G.; Nava-Villegas, Lorena; Hernández-Colin, Ana K.; Hernández-Alcántara, Areli E.; Zárate-Rodríguez, Pedro A.; Ignacio-Ibarra, Gregorio; Meillón-García, Luis A.; Espinosa-Bautista, Karla A.; Ledesma de la Cruz, Cindy; Barbosa-Loría, Diego M.; García-Castillo, Carolina; Balderas-Delgado, Carolina; Cabrera-García, Álvaro; Pérez-Zúñiga, Juan M.; Hernández-Ruiz, Eleazar; Villela-Peña, Atenas; Gómez Cortés, Sue Cynthia; Romero-Rodelo, Hilda; Garzón-Velásquez, Katheryn B.; Serrano-Hernández, Cristina; Martínez-Ríos, Annel; Pedraza-Solís, María Luisa; Martínez-Coronel, Jorge A.; Narváez-Davalos, Iris M.; García-Camacho, Alinka S.; Merino-Pasaye, Laura E.; Aguilar-Andrade, Carolina; Aguirre-Domínguez, Juan A.; Guzmán-Mera, Pedro G.; Delgado-de la Rosa, Elizabeth; Flores López, Perla E.; González-Aguirre, Lilia L.; Ramírez-Alfaro, Edgar M.; Vera-Calderón, Heidi; Meza-Dávalos, María Lizeth; Murillo-Cruz, Juan; Pichardo-Cepín, Yayra M.; Ramírez-Romero, Eva F..
Gac. méd. Méx ; 158(spe): M1-M51, ene. 2022. tab, graf
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1375542

RESUMO

resumen está disponible en el texto completo


Abstract Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent.

2.
Arch Med Res ; 52(6): 627-634, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33750595

RESUMO

BACKGROUND: Despite novel therapies, multiple myeloma (MM) remains an incurable malignancy, daratumumab (DARA) being a major game changer, may be a good option for treatment. AIMED OF THE STUDY: To assess the prescription patterns of DARA in patients with MM in Mexico. METHODS: 47 patients with MM were analyzed in 13 different hospitals in Mexico. RESULTS: Five (10.5%) of patients received DARA as first line therapy, 13 (27.5%) as second line, whereas 29 (62%) received its in ≥3rd line. In 32% DARA was used in combination with dexamethasone, 64% received DARA on a triple combination, and 4% as a 4 drug combination. Eighty three percent of patients had a response, including 32% in complete remission. Progression free survival (PFS) was higher in patients in ISS stage 1, and in patients achieving ≥PR. Overall survival (OS) was lower in patients not achieving ≥PR, in patients having increased LDH, and extramedullary disease. Grade 1-2 infusion related reactions were present in 34%, and grade 3-4 neutropenia and lymphopenia in 25 and 17% of the patients. CONCLUSIONS: In Mexico, 62% of patients with MM received DARA as a third or further line of treatment. DARA employed as a doublet or triplet combination is useful in relapsed/refractory patients with tolerable adverse events.


Assuntos
Mieloma Múltiplo , Anticorpos Monoclonais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Humanos , México , Mieloma Múltiplo/tratamento farmacológico , Prescrições
3.
Gac Med Mex ; 156(Suppl 1): S1-S45, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33103663

RESUMO

To identify this increasingly common pathology, known as multiple myeloma (MM), it is necessary to refer to the specific factors that characterize it; to this end, the classic criteria known as CRAB (hyperkalemia, renal failure, anemia, and lytic lesions) are available, in which renal failure is one of the most frequent complications. Recently, three indisputable biomarkers have been described for the diagnostic support for MM, which are: more than 10% of clonal plasma cells in bone marrow or, a biopsy that corroborates the presence of a plasmacytoma, light chain ratio ≥ 100 mg/dL and more than one focal lesion on magnetic resonance imaging. A differential diagnosis for plasma cell leukemia, solitary bone plasmacytoma, and extramedullary plasmacytoma should always be considered. Being this an incurable disease, a lot of research has been done regarding its therapeutic management, whose main objective is the disappearance of plasma cells and the patient clinical improvement. Melphalan was the first drug that showed a benefit in 1958 and afterward, with the addition of a steroid as a second drug, it was possible to improve response rates. Subsequently, different molecules were studied, forming multiple combinations, and achieving better rates of overall survival and progression-free survival. Years later, with the arrival of proteasome inhibitors such as bortezomib, and immunomodulators such as thalidomide and lenalidomide, an important turnaround in the disease has been seen, as deeper responses, more prolonged remissions, and improvement in the quality of life of patients have been achieved. This consensus has the purpose of integrating a group of Mexican specialists and promoting the updating of this pathology.


Para identificar una patología cada vez más común, conocida como mieloma múltiple, es necesario hacer alusión de los factores específicos que la caracterizan. Para ello existen los clásicos criterios conocidos como CRAB (hipercalcemia, insuficiencia renal, anemia y lesiones líticas), siendo la insuficiencia renal una de sus complicaciones más frecuentes. Recientemente se han descrito tres biomarcadores indiscutibles para el apoyo diagnóstico del mieloma múltiple, que son: más del 10% de células plasmáticas clonales en medula ósea o biopsia que corrobora la presencia de un plasmocitoma, relación de cadenas ligeras ≥ 100 mg/dl y más de una lesión focal en resonancia magnética. Se debe tomar siempre en cuenta el diagnóstico diferencial con leucemia de células plasmáticas, plasmocitoma óseo solitario y plasmocitoma extramedular. Al ser una enfermedad incurable, se ha investigado mucho en cuanto al manejo terapéutico, el cual tiene como objetivo principal la desaparición de las células plasmáticas y la mejoría clínica del paciente. El primer fármaco que demostró algún beneficio fue el melfalán en el año 1958 y posteriormente al adicionar un esteroide como segundo fármaco se logró mejorar las tasas de respuesta. Después se fueron estudiando diferentes moléculas, con las que se han realizado múltiples combinaciones, alcanzando mejores tasas de supervivencia global y supervivencia libre de progresión. Años más tarde, con la llegada de los inhibidores de proteosoma como el bortezomib, así como de los agentes inmunomoduladores como la talidomida y la lenalidomida, se presenta un giro importante en la enfermedad, ya que se logran respuestas más profundas, periodo de remisiones más prolongadas y mejoría en la calidad de vida de los pacientes. Este consenso tiene la finalidad de integrar a un grupo de especialistas mexicanos y promover la actualización de esta patología.


Assuntos
Mieloma Múltiplo/diagnóstico , Mieloma Múltiplo/terapia , Algoritmos , Humanos , México , Mieloma Múltiplo/complicações
4.
Clin Lymphoma Myeloma Leuk ; 20(6): e295-e303, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32192977

RESUMO

BACKGROUND: In the past decades, long-term survival outcomes for younger patients with acute myeloid leukemia (AML) have improved. Nonetheless, developing nations might be lagging behind, highlighting the need to assess real-world outcomes in such regions. METHODS: We performed a multicenter retrospective study, which included patients with AML diagnosed between January 2013 and December 2017 from 13 centers in Mexico. RESULTS: A total of 525 patients with AML met the inclusion criteria and were included in the study. Median age for the entire cohort was 47 years. The patients were classified according to cytogenetic risk: favorable 16.0%, intermediate 55.6%, and unfavorable 28.4%. Most patients received intensive chemotherapy (80.2%), and among these 74.1% underwent a 7 + 3 induction regimen. A complete remission was achieved in 71.3% of patients. Induction-related mortality occurred in 17.8% and we identify the following as independent risk factors: >60 years (odds ratio [OR] 2.09 [1.09-4.02]), Eastern Cooperative Oncology Group >2 (OR 4.82 [2.46-9.43]), prior solid tumor (OR 3.8 [1.24-11.59]) and active infection (OR 1.82 [1.06-3.12]). Further, allogeneic hematopoietic stem-cell transplantation (AlloHSCT) was performed in 8.2% in CR1. The 3-year overall survival (OS) was 34.8%. In a multivariate analysis, several factors were independently associated with a worse OS, including secondary AML (hazard ratio [HR] 2.14 [1.15-4.01]) and unfavorable cytogenetic risk (HR 1.81 [1.16-2.82]), whereas maintenance therapy (HR 0.53 [0.32-0.86]) and AlloHSCT (HR 0.40 [0.17-0.94]) were associated with better OS. CONCLUSIONS: This is the first multicenter report analyzing AML survival in Mexico. Challenges in this setting include a high induction-related mortality and low AlloHSCT rate, which should be addressed to improve outcomes.


Assuntos
Transplante de Células-Tronco Hematopoéticas , Leucemia Mieloide Aguda , Sistema de Registros , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Países em Desenvolvimento , Intervalo Livre de Doença , Feminino , Humanos , Leucemia Mieloide Aguda/mortalidade , Leucemia Mieloide Aguda/terapia , Masculino , México/epidemiologia , Pessoa de Meia-Idade , Indução de Remissão , Taxa de Sobrevida , Transplante Homólogo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...